Certifect

RSS

fipronil / amitraz / (S)-methoprene

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Certifect has been withdrawn at the request of the marketing-authorisation holder.

This EPAR was last updated on 27/07/2018

Authorisation details

Product details
Name
Certifect
Agency product number
EMEA/V/C/002002
Active substance
fipronil / amitraz / (S)-methoprene
International non-proprietary name (INN) or common name
fipronil / amitraz / (S)-methoprene
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QP53AX65
Publication details
Marketing-authorisation holder
Merial
Revision
5
Date of issue of marketing authorisation valid throughout the European Union
06/05/2011
Contact address
29 avenue Tony Garnier
69007 Lyon
France

Product information

18/04/2016 Certifect - EMEA/V/C/002002 - R/0011

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Ectoparasiticides for topical use

Therapeutic indication

Treatment and prevention of infestations in dogs by ticks (Ixodes ricinus, Dermacentor reticulatus, Rhipicephalus sanguineus, Ixodes scapularis, Dermacentor variabilis, Haemaphysalis elliptica, Haemaphysalis longicornis, Amblyomma americanum and Amblyomma maculatum) and fleas (Ctenocephalides felis and Ctenocephalides canis). Treatment of infestations by chewing lice (Trichodectes canis). Prevention of environmental flea contamination by inhibiting the development of all flea immature stages. The product can be used as part of a treatment strategy for the control of flea-allergy dermatitis. Elimination of fleas and ticks within 24 hours. One treatment prevents further infestations for five weeks by ticks and for up to five weeks by fleas.

The treatment indirectly reduces the risk of transmission of tick-borne diseases (canine babesiosis, monocytic ehrlichiosis, granulocytic anaplasmosis and borreliosis) from infected ticks for four weeks.

Assessment history

How useful was this page?

Add your rating